Machine learning model predicts radiotherapy response in nasopharyngeal carcinoma patients using gene expression data.

LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 -- Data readouts for CHS-114 and casdozokitug on track for 1H 2026 -- Q2 2025 ending cash, cash equivalents and marketable ...

Key Points Revenue (GAAP) exceeded analyst estimates by 10.2% for Q2 2025, with GAAP net revenue rising to $10.3 million, driven by growth in LOQTORZI sales. Non-GAAP EPS missed expectations at $(0.34 ...

A research team from Southern Medical University has developed a machine learning-based gene model that predicts whether ...

Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in fewer than one person out of 100,000 worldwide each year. Locally advanced ...

In the United States, a rolling submission of the first toripalimab Biologics License Application (BLA) is underway for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). The U.S ...

Nasopharyngeal carcinoma (NPC) is a unique epithelial malignancy arising from the superior aspect of the pharyngeal mucosal space, associated with latent Epstein-Barr virus infection in most cases.

LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 - - Data readouts for CHS-114 and casdozokitug on track for 1H 2026 - - Q2 2025 ending cash, cash equivalents and marketable ...